Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1139 • ACR Convergence 2020
Primary Non-adherence in Patients with Systemic Lupus Erythematosus
Ankoor Shah¹, Megan Clowse², Daniel Wojdyla¹ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC
Background/Purpose: Up to 50% of patients with systemic lupus erythematosus (SLE) are nonadherent to their medications, which increases the risk of renal failure and death…
Abstract Number: 1269 • ACR Convergence 2020
Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Stephen Paget¹, Jessica Berman¹, Medha Barbhaiya², Lisa Sammaritano², Kyriakos Kirou¹, John Carrino³, Musarrat Nahid⁴, Mangala Rajan⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ³Hospital for Special Surgery, Hackensack, NJ, ⁴Weill Cornell Medicine, New York
Background/Purpose: Frailty has been associated with increased disability and mortality in SLE. To our knowledge, no patient-reported frailty tool has been evaluated alongside a standard…
Abstract Number: 1285 • ACR Convergence 2020
Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with SLE
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Frailty has been associated with disability and mortality in SLE. Whether this association is confounded by sarcopenia, a degenerative loss of muscle mass and…
Abstract Number: 1301 • ACR Convergence 2020
Characterizing How SLE Patients Access Health Information Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Calgary, Calgary, Canada
Background/Purpose: The spread of misinformation related to COVID-19 has been especially acute for SLE patients as unsubstantiated claims regarding the efficacy of antimalarials for COVID-19…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 1670 • ACR Convergence 2020
Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset
Fatima Barbar-Smiley¹, Danlei Zhou², Joanne Drew², Bi Zhou², Cagri Yildirim-Toruner², Vidya Sivaraman³, Wael Jarjour⁴, Stacy Ardoin² and Chack-Yung Yu⁵, ¹Nationwide Children's Hospital/The Ohio State University, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital, Bexley, OH, ⁴The Ohio State University, Columbus, OH, ⁵Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Hypocomplementemia is a marked feature of systemic lupus erythematosus (SLE), which may be a result of consumption initiated by immune complexes between self-nuclear antigens…
Abstract Number: 1770 • ACR Convergence 2020
Lupus Low Disease Activity State Protects Against Pre-Term Birth
Michelle Petri¹, Jessica Li² and Daniel Goldman³, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus low disease activity state (LLDAS) (Ann Rheum Dis. 2016;75:1615–21.) combine both low disease activity (SLEDAI score of ≤4, PGA >=1 no flare, no…
Abstract Number: 1799 • ACR Convergence 2020
High Fat-Diet as a Catalyst to Lupus Development and Autoimmunity in MRL/lpr Mice
Hiba Ali¹, Juan Meng², Xuhua Shi², Linh Hellmers³, Swathi Dhulipala⁴, Patricia Kachur⁴, Therese Posas-Mendoza⁴, Robert Quinet⁵, William Davis⁵, Jerald Zakem⁴, Zongbing You² and Xin Zhang³, ¹Dept. of Rheumatology, Ochsner Medical Center, New Orleans, ²Tulane University Health Science Center, New Orleans, ³Institution of Translational Research, Ochsner Medical Center, New Orleans, ⁴Dept of Rheumatology, Ochsner Medical Center, New Orleans, ⁵Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with features of autoantibodies, skin rash, kidney and other multiple organ involvement. Evidence shows that obesity…
Abstract Number: 1817 • ACR Convergence 2020
Changes in Macular Capillary Network Measured with Optical Coherence Tomography-angiography in Patients with Systemic Lupus Erythematosus
Laura Pelegrin¹, Marc Figueras-Roca¹, Alvaro Olate-Perez¹, Javier Zarranz-Ventura¹, Ricardo Casaroli-Marano¹, Montse Morató¹, Vanesa Budi¹, José Ríos², Ricard Cervera³, Alfredo Adan¹ and Gerard Espinosa¹, ¹Hospital Clinic, Barcelona, Catalonia, Spain, ²Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Eye involvement in systemic lupus erythematosus (SLE) occurs in approximately one-third of patients, usually related to disease activity. An early diagnosis and treatment could…
Abstract Number: 1833 • ACR Convergence 2020
Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Hydroxychloroquine (HCQ) and vitamin D are both immunomodulators in SLE, but work through different mechanisms. Hydroxychloroquine has been proven to triple renal response to…
Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 0029 • ACR Convergence 2020
Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Emma Weeding¹, Andrea Fava¹, Jill Buyon², H. Michael Belmont³, Peter Izmirly⁴, Robert Clancy⁵, Jose Monroy-Trujillo⁶, Derek Fine⁶, William Apruzzese⁷, Harald Mischak⁸ and Michelle Petri⁹, ¹Johns Hopkins University, Baltimore, MD, ²Department of Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, ⁷., Boston, ⁸Multiple Institutions, Glasgow, United Kingdom, ⁹Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Current management of lupus nephritis (LN) is guided by histopathological features on kidney biopsy and measurement of proteinuria. Urine proteomics is a non-invasive source…
Abstract Number: 0254 • ACR Convergence 2020
LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
Manuel Ugarte-Gil¹, Rocío V. Gamboa-Cárdenas², Cristina Reátegui-Sokolova³, Victor Pimentel-Quiroz⁴, Mariela Medina², Claudia Elera-Fitzcarrald⁴, Francisco Zevallos², César A. Pastor-Asurza⁵, Jennifer Lofland⁶, Federico Zazzetti⁷, Chetan Karyekar⁸, Graciela Alarcón⁹ and Risto Perich-Campos⁵, ¹Department of Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ²Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, ⁴Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ⁵Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Buenos Aires, Argentina, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama
Background/Purpose: LLDAS and remission have been proposed as treatment goals for SLE patients. However, their impact on damage prevention in patients from Latin America has…
Abstract Number: 0271 • ACR Convergence 2020
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Alicia Malone¹, Alexandra Legge¹ and John Hanly¹, ¹Dalhousie University, Halifax, NS, Canada
Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
Abstract Number: 0289 • ACR Convergence 2020
Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, W. Winn Chatham¹, Hui-Chen Hsu¹ and John Mountz², ¹University of Alabama at Birmingham, Birmingham, AL, ²University Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: We previously showed that B-cell endogenous interferon-beta (IFNβ) at the transitional (Tr) stage correlates with development of anti-Smith (anti-Sm) and renal disease as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].